Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE) , a passively managed exchange traded fund launched on May 1, 2006.Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors.Sector ETFs also provide investors access to a broad group of companie ...

Core Viewpoint - The Invesco Pharmaceuticals ETF (PJP) provides broad exposure to the Healthcare - Pharma segment, appealing to both retail and institutional investors due to its low costs, transparency, flexibility, and tax efficiency [1][2]. Fund Overview - PJP is a passively managed ETF launched on June 23, 2005, with assets exceeding $257.58 million, positioning it as an average-sized ETF in the Healthcare - Pharma sector [3]. - The fund aims to match the performance of the Dynamic Pharmaceutical Intellidex Index, which evaluates U.S. pharmaceutical companies based on various investment criteria [4]. Cost Structure - The annual operating expenses for PJP are 0.56%, which is competitive within its peer group, and it has a 12-month trailing dividend yield of 1.07% [5]. Sector Exposure and Holdings - PJP is fully allocated to the Healthcare sector, with Eli Lilly & Co (LLY) making up approximately 5.24% of total assets, followed by Pfizer Inc (PFE) and Amgen Inc (AMGN). The top 10 holdings constitute about 47.34% of total assets [6][7]. Performance Metrics - Year-to-date, PJP has increased by roughly 9.35%, and it was up about 6.41% over the last 12 months as of August 19, 2025. The ETF has traded between $74.593 and $90.012 in the past 52 weeks, with a beta of 0.48 and a standard deviation of 15.82% over the trailing three-year period [8]. Alternatives - PJP holds a Zacks ETF Rank of 3 (Hold), indicating it is a viable option for investors seeking exposure to the Healthcare ETFs market. Other alternatives include the VanEck Pharmaceutical ETF (PPH) and the iShares U.S. Pharmaceuticals ETF (IHE), which have assets of $532.51 million and $571.47 million, respectively, with lower expense ratios of 0.36% and 0.39% [9][10].

The approval makes Wegovy the first GLP-1 class treatment authorized for MASH, a progressive liver condition estimated to affect around 5% of U.S. adults, according to the American Liver Foundation, as quoted on CNBC. This achievement expands Wegovy's use beyond diabetes and obesity, strengthening Novo Nordisk's position in the metabolic disease market. Previous studies have also shown the drug's effectiveness in lowering the risks of heart attack, stroke and cardiovascular-related death. Results From the E ...

Core Insights - The VanEck Pharmaceutical ETF (PPH) offers broad exposure to the Healthcare - Pharma segment, appealing to both institutional and retail investors due to its low cost and transparency [1][2] - The fund has assets exceeding $497.25 million and aims to match the performance of the MVIS US Listed Pharmaceutical 25 Index [3][4] Costs - PPH has an annual operating expense ratio of 0.36%, making it one of the cheaper options in the ETF space, with a 12-month trailing dividend yield of 2.27% [5] Sector Exposure and Top Holdings - The ETF's top holding is Eli Lilly & Co (LLY), which constitutes approximately 18.57% of total assets, followed by Johnson & Johnson (JNJ) and Novartis Ag (NVS). The top 10 holdings represent about 73.03% of total assets [6] Performance and Risk - As of July 22, 2025, PPH has a return of roughly 0.81% and is down about -4.46% year-to-date. The ETF has traded between $80.28 and $99.43 over the past 52 weeks, with a beta of 0.54 and a standard deviation of 14% for the trailing three-year period, indicating medium risk [7] Alternatives - PPH carries a Zacks ETF Rank of 3 (Hold), suggesting it is a reasonable option for investors seeking exposure to the Healthcare ETFs market. Other alternatives include Invesco Pharmaceuticals ETF (PJP) and iShares U.S. Pharmaceuticals ETF (IHE) [8][9]

Core Viewpoint - The Invesco Pharmaceuticals ETF (PJP) is a smart beta ETF designed to provide broad exposure to the healthcare sector, specifically focusing on U.S. pharmaceutical companies [1][5][6]. Fund Overview - PJP was launched on June 23, 2005, and has accumulated over $239.95 million in assets, categorizing it as an average-sized ETF within the healthcare sector [1][5]. - The fund aims to match the performance of the Dynamic Pharmaceutical Intellidex Index, which evaluates companies based on various investment merit criteria [5][6]. Cost and Expenses - PJP has an annual operating expense ratio of 0.56%, which is competitive with most peer products in the healthcare ETF space [7]. - The fund offers a 12-month trailing dividend yield of 1.16% [7]. Sector Exposure and Holdings - The ETF is fully allocated to the healthcare sector, with approximately 100% of its portfolio dedicated to this area [8]. - Eli Lilly & Co (LLY) constitutes about 5.41% of the fund's total assets, followed by Amgen Inc (AMGN) and Pfizer Inc (PFE). The top 10 holdings represent approximately 46.64% of total assets [9]. Performance Metrics - As of July 10, 2025, PJP has gained roughly 0.8% year-to-date and approximately 2.82% over the past year [11]. - The fund has traded between $74.59 and $89.61 in the last 52 weeks, with a beta of 0.47 and a standard deviation of 15.71% over the trailing three-year period, indicating a higher risk profile compared to peers [11]. Alternatives - Other ETFs in the pharmaceutical space include iShares U.S. Pharmaceuticals ETF (IHE) and VanEck Pharmaceutical ETF (PPH), which have lower expense ratios of 0.39% and 0.36%, respectively [13]. - Investors seeking lower-risk options may consider traditional market cap weighted ETFs that aim to match healthcare sector returns [13].